MyMD’s experienced research and development team has partnered with academic founders and key opinion leaders to identify and utilize synthetic therapeutics for treatment of autoimmune disease, aging and anxiety.
Clinical Trials
Research shows that, at only about 146 Daltons, MYMD-1 is the first oral TNF-a regulator capable of crossing the blood-brain barrier, which should enable it to address Alzheimer’s and other brain-related diseases. Unlike other therapies, MYMD-1 selectively blocks TNF-α when it becomes overactivated in autoimmune diseases and cytokine storms, but does not block it from doing its normal job of being a first responder to any routine type of moderate infection.
Learn more about MYMD-1MyMD drug candidates have been the subject of peer-reviewed research publications from distinguished institutions.
MYMD-1, a Novel Immunometabolic Regulator, Ameliorates Autoimmune Thyroiditis via Suppression of Th1 Responses and TNF-α Release
Read the ArticleMYMD-1, a novel alkaloid compound, ameliorates the course of experimental autoimmune encephalomyelitis
Read the Article